ABIOMED Inc. (ABMD) reported third quarter GAAP EPS of $0.30 after the bell Tuesday, up from $0.11 a year ago.
The company also announced that the FDA has approved its Impella RP System, a percutaneous single access heart pump designed for right heart support.
ABIOMED gapped open sharply higher Wednesday, but pulled back during the first 45 minutes of trade, before settling into a range. The stock finished down by 11.31 at $49.94 on the highest volume of the year. ABIOMED leaped past resistance and set a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News